Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Moderate-to-Severe Atopic Dermatitis

In brief

The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Key facts

Study ID

NCT03985943

Run by

Galderma R&D

People needed

941

Starts

2019-06-27

Expected to finish

2022-08-11

Last updated by the study team

2024-08-14

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Galderma Investigational Site 8578 — Cerritos, California, United States
• Galderma Investigational Site 8636 — Fountain Valley, California, United States
• Galderma Investigational Site 8888 — Fullerton, California, United States
• Galderma Investigational Site 8686 — Lomita, California, United States
• Galderma Investigational Site 8674 — Los Angeles, California, United States
• Galderma Investigational Site 8125 — San Francisco, California, United States
• Galderma Investigational Site 8895 — Santa Ana, California, United States
• Galderma Investigational Site 8608 — Santa Monica, California, United States
• Galderma Investigational Site 8897 — Brandon, Florida, United States
• Galderma Investigational Site 8805 — Cape Coral, Florida, United States
• Galderma Investigational Site 8902 — Doral, Florida, United States
• Galderma Investigational Site 8804 — Hialeah, Florida, United States
• Galderma Investigational Site 8711 — Jacksonville, Florida, United States
• Galderma Investigational Site 8710 — Miami, Florida, United States
• Galderma Investigational Site 8801 — Miami, Florida, United States
• Galderma Investigational Site 8737 — Miami, Florida, United States
• Galderma Investigational Site 8708 — Miami, Florida, United States
• Galderma Investigational Site 8806 — Miami Lakes, Florida, United States
• Galderma Investigational Site 8800 — Miami Lakes, Florida, United States
• Galderma Investigational Site 8734 — Pembroke Pines, Florida, United States
• Galderma Investigational Site 8744 — Macon, Georgia, United States
• Galderma Investigational Site 8728 — Newnan, Georgia, United States
• Galderma Investigational Site 8887 — Union City, Georgia, United States
• Galderma Investigational Site 8890 — Blackfoot, Idaho, United States
• Galderma Investigational Site 8880 — North Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.